Core Insights - Bioxytran, Inc. is advancing treatments for ischemic stroke and Alzheimer's disease through its universal oxygen carrier (UOC) technology, which is detailed in a newly published book by Prof. Avraham Mayevsky [1][2][3] - The UOC is designed to replace hyperbaric oxygen treatment (HBOT) by delivering therapeutic oxygen at the cellular level, providing a significant improvement over traditional methods [2] - The Mongolian gerbil model is utilized for research due to its unique brain structure that lacks compensatory mechanisms for blood flow, making it ideal for studying stroke pathophysiology [3][4] Company Overview - Bioxytran, Inc. focuses on developing complex carbohydrate-based therapeutics to meet critical medical needs across three core platforms: virology, cancer metastasis, and oxygen transport [5] - The company is also working on programs for pulmonary fibrosis and stroke treatment, with a specific product, BXT-25, showing potential to significantly reduce the time until treatment in emergency situations [5]